• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Reminyl (galantamine hydrobromide)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Reminyl (galantamine hydrobromide)

  • Profile

Profile

Contact Information

Contact: Janssen
Website: https://www.janssen.com/

Currently Enrolling Trials

    Show More

    General Information

    Reminyl is an Alzheimer's treatment derived from the bulbs of the daffodil, Narcissus pseudonarcissus. It is believed that neurons producing the neurotransmitter acetylcholine degenerate in the brains of patients with Alzheimer's disease. This loss of acetylcholine has been correlated with decreased cognitive function (thinking, remembering and reasoning). Reminyl works to increase the concentration of acetylcholine by blocking the action of acetylcholinesterase, an enzyme that catalyzes the hydrolysis (break down) of acetylcholine.

    An estimated four million Americans have Alzheimer's disease — a progressive loss of cognitive function so severe that it interferes with an individual's ability to function. The disorder is the third-most expensive illness in the United States, behind only heart disease and cancer.

    Reminyl was developed by the Janssen Research Foundation under a co-development and licensing agreement with the UK-based Shire Pharmaceuticals. The drug will be marketed by Janssen Pharmaceutica and Ortho-McNeil Pharmaceutical in the United States.

    Mechanism of Action

    Galantamine, a tertiary alkaloid, is a competitive and reversible inhibitor of acetylcholinesterase. While the precise mechanism of galantamine's action is unknown, it may exert its therapeutic effect by enhancing cholinergic function. This is accomplished by increasing the concentration of acetylcholine through reversible inhibition of its hydrolysis by cholinesterase. If this mechanism is correct, galantamine's effect may lessen as the disease process advances and fewer cholinergic neurons remain functionally intact (from Reminyl prescribing information).

    Side Effects

    Adverse events reported with Reminyl use include, but are not limited to, the following:

    • Nausea
    • Vomiting
    • Diarrhea
    • Anorexia
    • Weight loss

    The most frequent adverse events associated with the use of Reminyl can be minimized by following the recommended dosage and administration.

    Because this list is not all-inclusive, please consult a physician to discuss any side effects and the individual appropriateness of the drug.

    Dosage/Administration

    Reminyl is given in a tablet formulation, with 4 mg, 8 mg or 12 mg dosages. The drug should be taken twice a day, preferably with morning and evening meals.

    Clinical Trial Results

    In trials ranging from 12 to 26 weeks, the effectiveness of Reminyl was measured using two primary tools: subjects' abilities in terms of memory, orientation, reasoning and language were assessed using the cognitive portion of the Alzheimer's Disease Assessment Scale (ADAS-cog). Across all trials, results demonstrated that more subjects taking Reminyl showed significant improvement in their cognitive performance than subjects taking placebo.

    The second primary measure of effectiveness was the Clinician's Interview-Based Impression of Change plus Caregiver Information (CIBIC-plus), which provides an overall assessment of patient functioning - including behavior, organized thinking and activities of daily living (such as dressing, eating and managing family finances). The CIBIC-plus results from all trials also showed that the overall scores for subjects taking Reminyl were statistically superior to placebo.

    Additional Information

    For more information on Reminyl, please visit Janssen Pharmaceutica.

    Additional information on Alzheimer's disease can be obtained by visiting the Alzheimer's Association.

    Approval Date: 2001-02-01
    Company Name: Janssen Pharmaceuticals
    Back to Listings

    Upcoming Events

    • 16Feb

      Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

    • 21May

      WCG MAGI Clinical Research Conference – 2023 East

    Featured Products

    • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

      Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    Featured Stories

    • Revamp-360x240.png

      Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

    • AskTheExpertsGreen-360x240.png

      Ask the Experts: Managing Investigational Products

    • SurveywBlueBackground-360x240.png

      Survey Outlines Site Challenges, Successes on Diversity

    • PatientCentricity-360x240.png

      Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing